|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
94,014,000 |
Market
Cap: |
1.69(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$11.39 - $24.81 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 4.9 |
Insider 3/6 Months : 5.5 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of cancer therapies. Co.'s two primary product candidates are, SNDX-5613 and SNDX-6352 or axatilimab. Co. is developing SNDX-5613, targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1) protein for the treatment of MLL-rearranged acute leukemias and nucleophosmin 1 mutant acute myeloid leukemia, as well as axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor. Co. has a collaboration and license agreement with Incyte Corporation for the development and commercialization of axatilimab.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
1,250 |
1,250 |
1,250 |
Total Buy Value |
$0 |
$25,037 |
$25,037 |
$25,037 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
632,588 |
Total Sell Value |
$0 |
$0 |
$0 |
$14,264,017 |
Total People Sold |
0 |
0 |
0 |
7 |
Total Sell Transactions |
0 |
0 |
0 |
24 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Metzger Michael A |
President and COO |
|
2020-11-04 |
4 |
AS |
$20.31 |
$2,031,410 |
D/D |
(100,000) |
17,659 |
|
- |
|
Metzger Michael A |
President and COO |
|
2020-11-04 |
4 |
OE |
$7.20 |
$720,000 |
D/D |
100,000 |
117,659 |
|
- |
|
Meyers Michael L. |
SVP, Chief Medical Officer |
|
2020-07-31 |
4 |
A |
$7.97 |
$21,240 |
D/D |
2,665 |
13,395 |
|
- |
|
Meyers Michael L. |
SVP, Chief Medical Officer |
|
2020-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,500 |
10,730 |
|
- |
|
Metzger Michael A |
President and COO |
|
2020-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
17,659 |
|
- |
|
Morrison Briggs |
Chief Executive Officer |
|
2020-02-04 |
4 |
B |
$8.00 |
$100,000 |
D/D |
12,500 |
43,900 |
0.01 |
- |
|
Shea Richard P |
Chief Financial Officer |
|
2020-01-31 |
4 |
A |
$7.97 |
$11,995 |
D/D |
1,505 |
7,121 |
|
- |
|
Morrison Briggs |
Chief Executive Officer |
|
2019-10-10 |
4 |
B |
$5.40 |
$59,400 |
D/D |
11,000 |
31,400 |
0.01 |
- |
|
Shea Richard P |
Chief Financial Officer |
|
2019-07-31 |
4 |
A |
$4.89 |
$6,851 |
D/D |
1,401 |
5,616 |
|
- |
|
Morrison Briggs |
Chief Executive Officer |
|
2019-05-13 |
4 |
B |
$7.29 |
$52,517 |
D/D |
7,200 |
20,400 |
0.01 |
- |
|
Morrison Briggs |
Chief Executive Officer |
|
2019-05-09 |
4 |
B |
$7.56 |
$99,726 |
D/D |
13,200 |
13,200 |
0.01 |
- |
|
Meyers Michael L. |
SVP, Chief Medical Officer |
|
2019-03-21 |
4/A |
B |
$4.87 |
$39 |
D/D |
8 |
7,230 |
0.01 |
- |
|
Meyers Michael L. |
SVP, Chief Medical Officer |
|
2019-03-21 |
4 |
B |
$4.87 |
$5,436 |
D/D |
1,104 |
7,222 |
0.01 |
- |
|
Metzger Michael A |
President and COO |
|
2019-01-31 |
4 |
A |
$4.76 |
$12,657 |
D/D |
2,659 |
2,659 |
|
- |
|
Shea Richard P |
Chief Financial Officer |
|
2019-01-31 |
4 |
A |
$4.76 |
$12,000 |
D/D |
2,521 |
4,215 |
|
- |
|
Meyers Michael L. |
SVP, Chief Medical Officer |
|
2019-01-31 |
4 |
A |
$4.76 |
$17,707 |
D/D |
3,720 |
6,118 |
|
- |
|
Meyers Michael L. |
SVP, Chief Medical Officer |
|
2018-10-30 |
4 |
B |
$4.79 |
$958 |
D/D |
200 |
2,398 |
0.01 |
- |
|
Lampert Mark N |
10% Owner |
|
2018-06-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,000,000) |
85,038 |
|
- |
|
Ordentlich Peter |
Chief Scientific Officer |
|
2018-04-03 |
4 |
AS |
$15.00 |
$112,500 |
D/D |
(7,500) |
0 |
|
- |
|
Ordentlich Peter |
Chief Scientific Officer |
|
2018-04-03 |
4 |
OE |
$3.08 |
$23,100 |
D/D |
7,500 |
7,500 |
|
- |
|
Ordentlich Peter |
Chief Scientific Officer |
|
2017-05-17 |
4 |
AS |
$15.00 |
$75,000 |
D/D |
(5,000) |
0 |
|
- |
|
Ordentlich Peter |
Chief Scientific Officer |
|
2017-05-17 |
4 |
OE |
$3.08 |
$2,255 |
D/D |
732 |
5,000 |
|
- |
|
Royston Ivor |
|
|
2017-03-20 |
4 |
D |
$13.75 |
$1,718,750 |
I/I |
(125,000) |
625,545 |
|
- |
|
Mpm Bioventures Iv Strategic Fund, L.p. |
10% Owner |
|
2016-03-08 |
4 |
A |
$0.00 |
$0 |
I/I |
2,168,691 |
2,168,691 |
|
- |
|
Halak Brian K |
10% Owner |
|
2016-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,641 |
5,641 |
|
- |
|
208 Records found
|
|
Page 8 of 9 |
|
|